医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Panagene Signs Off with Dako to Supply PNA Oligomer Component

2013年02月22日 PM05:25
このエントリーをはてなブックマークに追加


 

DAEJEON, South Korea

Panagene announced it has signed a supply agreement with Dako Denmark A/S to supply PNA oligomer key component for incorporation into Dako’s diagnostic or research products. Dako, an Agilent Technologies Company since June 2012, is a leading global provider of tissue-based cancer diagnostic solutions. Under the agreement, Panagene will be the exclusive supplier of PNA probes which are raw materials for Dako’s diagnostic products.

PNA (Peptide Nucleic Acid) is an artificially synthesized DNA analogue which has higher binding affinity, specificity and sensitivity to the target and high biological/chemical stability. Panagene produce PNA probe of high quality and yield by its proprietary synthesis technology and has supplied its PNA probe to several multinational companies within in vitro diagnostics.

“We are pleased to manufacture and supply PNA probes to Dako for incorporation into their products. This agreement proves again that we are the world leader in the production of high quality PNA probes for research and diagnostic applications,” said Dr. Sung Kee Kim, President and CEO of Panagene.

Panagene is a worldwide custom PNA (peptide nucleic acid) oligomer provider, and has focused on developing various molecular diagnostic products based on PNA oligomers. With strong patent portfolio for manufacturing PNA products, Panagene succeed to commercialize diagnostic kits for somatic mutation and infectious disease. Compared with DNA-based diagnostic products, ones with PNA give higher sensitivity and stability.

CONTACT

Panagene Inc.
Ji Ah Choi
Deputy General Manager / Strategic
Planning Team
54, Techno 10-ro, Yuseong-gu
Daejeon, 305-510,
Korea
Tel: +82-42-861-9295
Fax: +82-42-861-9297
Mobile:
+82-10-6423-1687
Email: jiah.choi@panagene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高